NVO

Business Context and Reporting Period

Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2004
Reporting Currency: Danish Kroner (DKK)
Business Overview: Novo Nordisk is a global healthcare company and the world leader in diabetes care. It operates two primary segments: Diabetes Care (insulin analogues, human insulin, oral antidiabetic drugs) and Biopharmaceuticals (hemostasis management, growth hormone therapy, hormone replacement therapy). The company employs approximately 20,250 people across 78 countries and markets products in 179 countries.

Key Financial Metrics

The following metrics are reported in DKK millions unless otherwise noted.

Material Changes vs. Prior Period

• Profitability: Net profit under IFRS increased to DKK 5,013 million in 2004 from DKK 4,833 million in 2003. However, on a US GAAP basis, net profit decreased by 3% compared to 2003, primarily due to accounting differences regarding acquired in-process R&D, investments in R&D companies, and goodwill.
• Cash Flow: Free cash flow improved by DKK 432 million to DKK 4,278 million, driven largely by a reduction in the average number of credit days for trade debtors.
• Capital Expenditure: Net capital expenditure rose to DKK 3.0 billion (up from DKK 2.3 billion in 2003), exceeding the long-term target of 10% of sales due to timing shifts in projects and capacity expansions for insulin analogues (specifically Levemir) in Denmark, the US, Brazil, and China.
• Debt: Long-term debt increased to DKK 1,188 million from DKK 753 million in 2003.
• Share Buyback: The company repurchased 6,480,000 B shares (approx. DKK 2 billion) under a DKK 5 billion program announced in April 2004.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Investments: Novo Nordisk expects to invest approximately DKK 4 billion in fixed assets in 2005, with a significant portion outside Denmark, driven by capacity expansion for Levemir.
• R&D: R&D expenditure is expected to remain at approximately 15% of sales.
• Dividend: The Board proposed a dividend of DKK 4.80 per share for the 2004 fiscal year.

• The Diabetes Care segment (71% of sales) continues to grow due to the global increase in diabetes prevalence, conversion to insulin analogues, and new delivery devices.
• The Biopharmaceuticals segment saw double-digit growth in hemostasis management (NovoSeven) and growth hormone therapy, though hormone replacement therapy remains negatively impacted by studies on long-term risks.

• Regulatory & Pricing: Exposure to government-mandated price decreases, reimbursement rule changes, and regulatory approvals (FDA, EMEA).
• Patents: While major insulin analogue patents expire in 2011+, Activelle/Activella faces patent expiration in the US in 2006 and Europe in 2009. NovoSeven patents expire around 2011 (2008 in Japan).
• Market Risks: Significant exposure to foreign exchange rates (USD, JPY, GBP) and interest rate fluctuations. A 5% weakening of the DKK against all currencies would decrease the fair value of financial positions by DKK 294 million.
• Off-Balance Sheet: Credit guarantees of up to 15% on sold trade debtors in Japan (DKK 57 million exposure in 2004).

• Aradigm Transaction: Completed a restructuring transaction with Aradigm Corporation in January 2005, acquiring full rights to the AERx insulin Diabetes Management System for approx. DKK 300 million.
• Ferrosan Divestment: Completed the sale of its entire shareholding in Ferrosan A/S in February 2005, expecting to record an income of approx. DKK 250 million in 2005.

Investor Verification Checklist

• US GAAP vs. IFRS Reconciliation: Verify the specific adjustments causing the 3% decline in US GAAP net profit versus the IFRS increase, particularly regarding goodwill and in-process R&D.
• Patent Expiration Timeline: Confirm the impact of the 2006 US patent expiration for Activelle/Activella on future revenue projections.
• Capital Expenditure Utilization: Monitor the completion and ROI of the DKK 4 billion investment plan for 2005, specifically the Levemir capacity expansions.
• Foreign Exchange Sensitivity: Assess the impact of DKK/EUR fixed rate policy on the reported sensitivity analysis regarding USD and JPY exposure.
• Dividend Payout Ratio: Compare the proposed DKK 4.80 dividend against the company's stated target of aligning with comparable companies.